期刊
ONCOGENE
卷 37, 期 15, 页码 1949-1960出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41388-017-0077-z
关键词
-
资金
- AMC PhD Scholarship
- Dutch Cancer Society (KWF) [UVA 2014-6839, AMC2016.1-10460]
- National Institutes of Health (Bethesda, MD
- NIH) [R01HL118281, R01HL123904, R01HL132071, R35HL135795]
- AA & MDS International Foundation (Rockville, MD)
- Robert Duggan Charitable Fund (Cleveland, OH)
Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of D-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据